Nanomedicine formulations offer a promising approach to enhance the therapeutic index of antiviral drugs by improving pharmacokinetics and targeting capabilities.
May enhance antiviral delivery without changing practice; leaves open randomized trials for confirmation.
The activity of antiviral drugs could be improved with nanomedicine formulations. Indeed, nanoparticles can affect the fate of the encapsulated drugs, allowing controlled release kinetics, enhanced bioavailability, modified pharmacokinetics, and reduced side effects. In addition, the physicochemical properties of nanocarriers can enable their capability to target specific sites and to interact with virus structures. In this regard, nanomedicines can be considered an opportunity to enhance the therapeutic index of antivirals. Efficacy, safety, and manufacturing issues need to be carefully assessed to bring this promising approach to the clinic.
No takes yet. Share an insight, caveat, or question.
Lembo et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: